1. An immunogenic composition comprising (i) agonist of TLR7, (ii) an insoluble metal salt, and (iii) at least one antigen S.aureus, antigen selected from EsxA S.aureus, antigen EsxB S.aureus, non-toxic mutant S. hemolysin aureus, Sta006 antigen and / or antigen Sta011.2. The immunogenic composition of para. 1, containing antigen EsxA S.aureus, antigen EsxB S.aureus, non-toxic mutant hemolysin S.aureus, and antigen Sta006 Sta011.3 antigen. The immunogenic composition of para. 1, which further comprises (iv) bufer.4. The immunogenic composition of para. 1, wherein said composition has a pH of 6-8.5. Composition according to Claim. 1, wherein the TLR7 agonist comprises at least one adsorbing molecule that allows it to be adsorbed on insoluble agonist metalla.6 salts. The composition of claim. 5, wherein said absorbent molecules are phosphate or fosfonat.7. The composition of claim. 1, wherein said agonist of TLR7 has the formula (C), (D), (E), (F), (G), (H), (I), (II), (J) or (K ) or preferably formula (Κ ), defined in this specification zayavki.8. Composition according to Claim. 1, where TLR7 agonist is one of compounds 1-102 as defined in WO2012 / 031140, or a pharmaceutically acceptable sol.9. Composition according to Claim. 1, where TLR7 agonist is a compound K2.10. Composition according to Claim. 1, wherein the metal salt is an insoluble salt alyuminiya.11. The composition of claim. 10 wherein said aluminum salt is a hydroxide alyuminiya.12. A composition according to claim. 10 having a concentration of Al, component 10-500 g / ml.13. Composition according to Claim. 1, where> 80% of the TLR7 agonist is adsorbed onto the insoluble salts metalla.14. The composition of claim. 3, wherein said buffer is histidine bufer.15. The composition of claim 1 comprising four antigen:. (i) a polypeptide comprising Antiga1. Иммуногенная композиция, содержащая (i) агонист TLR7, (ii) нерастворимую соль металла и (iii) по меньшей мере один антиген S.aureus, выбранный из антигена Esx
